Acumen Pharmaceuticals (ABOS) Non Operating Income (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Non Operating Income of $412000.0 for Q1 2026, up 575.41% sequentially from $61000.0 in Q4 2025, and down 73.82% YoY from $1.6 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Non Operating Income (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Non Operating Income for 7 years, with the latest figure at $412000.0 in Q1 2026.
- Quarterly Non Operating Income fell 73.82% year-over-year to $412000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 87.12% YoY) and the FY2025 annual result came in at $2.5 million, down 78.64% from the prior year.
- Non Operating Income advanced to $412000.0 in Q1 2026 per ABOS's latest filing, from $61000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $3.8 million in Q2 2024 and troughed at $61000.0 in Q4 2025.
- A 5-year average of $1.5 million and a median of $1.6 million in 2025 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income soared 6400.0% in 2022, then slumped 97.52% in 2025.
- Over 5 years, Non Operating Income stood at $1.4 million in 2022, then surged by 43.92% to $2.0 million in 2023, then gained by 22.83% to $2.4 million in 2024, then tumbled by 97.5% to $61000.0 in 2025, then jumped by 575.41% to $412000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $412000.0, $61000.0, and $62000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | -162,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -162,000.00 |
| Mar 31, 2026 | 412,000.00 |
| Dec 31, 2025 | 61,000.00 |
| Sep 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 1.57 Mn |
| Dec 31, 2024 | 2.44 Mn |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 3.84 Mn |
| Mar 31, 2024 | 2.90 Mn |
| Dec 31, 2023 | 1.99 Mn |
| Sep 30, 2023 | 3.08 Mn |
| Jun 30, 2023 | 1.87 Mn |
| Mar 31, 2023 | 1.83 Mn |
| Dec 31, 2022 | 1.38 Mn |
| Sep 30, 2022 | 663,000.00 |
| Jun 30, 2022 | 260,000.00 |
| Mar 31, 2022 | 76,000.00 |
| Dec 31, 2021 | 62,000.00 |
| Sep 30, 2021 | 14,000.00 |